Rhenium

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Retrieved on: 
Monday, March 11, 2024
Fast Track, Breast cancer, Central nervous system, PSTV, Cohort, Rhenium, FDA, Cancer, Data monitoring committee, Learning, Therapy, CNS, Plus Therapeutics, Patient, DSMB, LM, Pharmaceutical industry

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

Key Points: 
  • Three patients were dosed as part of Cohort 5, bringing the total to 18 patients dosed in the ReSPECT-LM trial to date.
  • There have been no dose limiting toxicities observed to date with administered radiation doses up to 66.14 millicuries in Cohort 5, a ten-fold increase over Cohort 1.
  • The Company plans to initiate dosing in Cohort 6 in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval.
  • In addition, five new clinical trial sites were added to this trial over the last year, bringing the total number of sites to seven.

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024
Glioblastoma, Breast cancer, PSTV, Rhenium, Decompression (diving), FDA, Food, GMP, PD-1, Ependymoma, Conference, Safety, Plus Therapeutics, Respect, Therapy, Food and Drug Administration, Webcast, Patient, CSF, LM, PD-L1, Pharmaceutical industry

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.
  • Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose.
  • Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Plus Updates Financial and Cash Guidance for 2024

Retrieved on: 
Monday, December 18, 2023
Therapy, Burn, Central nervous system, Cancer, Patient, Rhenium, Plus Therapeutics, PSTV, Research institute, CNS, LM, Pharmaceutical industry

AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.

Key Points: 
  • AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.
  • Plus is currently in the second year of a Cancer Prevention and Research Institute of Texas (CPRIT) award totaling $17.8 million.
  • The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.
  • “This combination of forecasted non-dilutive grant revenue and debt restructuring significantly strengthens our balance sheet and reduces our burn,” said Andrew Sims, Chief Financial Officer of Plus Therapeutics.

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

Retrieved on: 
Tuesday, December 12, 2023
CSF, Patient, Ecosystem, Partnership, Neoplasm, Cerebrospinal fluid, Learning, PSTV, Cancer prevention, Caregiver, Research, FDA, Doctor of Philosophy, Cancer, Therapy, CNS, Texas Medical Center, LM, Plus Therapeutics, Central nervous system, Diagnosis, Rhenium, Fast Track, Research institute

This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).

Key Points: 
  • This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).
  • K2bio is based in Houston and is part of the Texas Medical Center life sciences ecosystem specializing in all aspects of translational cancer diagnostic and therapeutic research and development.
  • “K2bio is a leader in enabling rapid diagnostic and therapeutic progress for innovative companies such as Plus,” said Colby Suire, PhD, acting President and CEO of K2bio.
  • Patients interested in learning more about the ReSPECT-LM trial can visit ClinicalTrials.gov ( NCT05034497 ).

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

Retrieved on: 
Wednesday, November 15, 2023
Therapy, PSTV, Glioblastoma, Patient, Neuro, Conference, Plus Therapeutics, Rhenium, Neurosurgery, Neuro-oncology, Neurology, Society, SNO, KOL, Decompression (diving), Pharmaceutical industry, Medicine

To register, click here.

Key Points: 
  • To register, click here.
  • The event will feature presentations from neuro-oncology expert and principal investigator Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) and neurosurgeons Toral Patel, M.D.
  • Brain Institute) and John Floyd, M.D.
  • A live question and answer session will follow the formal presentations.

Global Graphene and 2D Materials Research Report 2024 with Market Forecasts to 2034 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Technology, Batteries, Chemicals, Plastics, Manufacturing, Attention, Market, Research, Rhenium disulfide, Electronics, Quantum, Rhenium diselenide, SWOT, Lubricant, 2D, Clothing, CVD, MXenes, Boron nitride, Original equipment manufacturer, Filtration, Graphene, Carbon fibers, Rhenium

The Global Market for Graphene and 2D Materials 2024-2034 is the most comprehensive and up-to date report on graphene and 2D materials currently available.

Key Points: 
  • The Global Market for Graphene and 2D Materials 2024-2034 is the most comprehensive and up-to date report on graphene and 2D materials currently available.
  • This in-depth graphene market report provides a comprehensive analysis of the global graphene industry.
  • The Global Market for Graphene and 2D Materials 2024-2034 contains:
    Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2034 and main players.
  • Assessment of graphene materials (CVD graphene, graphene nanoplatelets, graphene oxide, etc), intermediate products (graphene masterbatches, dispersions, etc) and final products with graphene embedded (e.g.

6K Additive Receives Third-Party Recycled Content Certification from Sustainability Verification Leader SCS Global Services

Retrieved on: 
Wednesday, November 29, 2023
Carbon, Chemistry, Foresight, Porosity, Copper, Certification, SCS, Tungsten, Niobium, Nickel, Rhenium, Stainless steel, Titanium, Environment, LCA

PITTSBURGH, Nov. 29, 2023 /PRNewswire/ -- 6K Additive, a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys, announced today that its titanium powder (Ti-6AL-4V) has been independently certified by Scientific Certification Systems (SCS) Global Services, a global third-party auditing and certification organization, for achieving a minimum 95% post-consumer recycled titanium content. The SCS Recycled Content Certification evaluates products made from pre-consumer or post-consumer material diverted from the waste stream. This certification measures the percentage of recycled content for the purpose of making an accurate claim in the marketplace.

Key Points: 
  • PITTSBURGH, Nov. 29, 2023 /PRNewswire/ -- 6K Additive , a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys, announced today that its titanium powder (Ti-6AL-4V) has been independently certified by Scientific Certification Systems (SCS) Global Services, a global third-party auditing and certification organization, for achieving a minimum 95% post-consumer recycled titanium content.
  • The SCS Recycled Content Certification evaluates products made from pre-consumer or post-consumer material diverted from the waste stream.
  • "We are thrilled that our commitment to sustainability has been recognized by a leading organization such as SCS Global Services through their certification process.
  • Companies interested in working with 6K Additive regarding their specific powder requirements are urged to visit 6K Additive's website 6KAdditive.com .

6K Additive Receives Third-Party Recycled Content Certification from Sustainability Verification Leader SCS Global Services

Retrieved on: 
Wednesday, November 29, 2023
Carbon, Chemistry, Foresight, Porosity, Copper, Certification, SCS, Tungsten, Niobium, Nickel, Rhenium, Stainless steel, Titanium, Environment, LCA

PITTSBURGH, Nov. 29, 2023 /PRNewswire/ -- 6K Additive, a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys, announced today that its titanium powder (Ti-6AL-4V) has been independently certified by Scientific Certification Systems (SCS) Global Services, a global third-party auditing and certification organization, for achieving a minimum 95% post-consumer recycled titanium content. The SCS Recycled Content Certification evaluates products made from pre-consumer or post-consumer material diverted from the waste stream. This certification measures the percentage of recycled content for the purpose of making an accurate claim in the marketplace.

Key Points: 
  • PITTSBURGH, Nov. 29, 2023 /PRNewswire/ -- 6K Additive , a division of 6K Inc. and leader in the sustainable production of materials for additive manufacturing and metal alloys, announced today that its titanium powder (Ti-6AL-4V) has been independently certified by Scientific Certification Systems (SCS) Global Services, a global third-party auditing and certification organization, for achieving a minimum 95% post-consumer recycled titanium content.
  • The SCS Recycled Content Certification evaluates products made from pre-consumer or post-consumer material diverted from the waste stream.
  • "We are thrilled that our commitment to sustainability has been recognized by a leading organization such as SCS Global Services through their certification process.
  • Companies interested in working with 6K Additive regarding their specific powder requirements are urged to visit 6K Additive's website 6KAdditive.com .

Global Graphene and 2D Materials Research Report 2024-2034: Emerging Applications in Quantum Dots and Fuel Cells

Retrieved on: 
Wednesday, November 15, 2023
Attention, Market, Research, Rhenium disulfide, Investment, Electronics, Quantum, Rhenium diselenide, Original equipment manufacturer, SWOT, Lubricant, Clothing, CVD, MXenes, Boron nitride, Filtration, Graphene, Carbon fibers, Rhenium

The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.

Key Points: 
  • The Global Market for Graphene and 2D Materials 2024-2034 stands as the most comprehensive and current report on graphene and 2D materials available today.
  • Emerging applications of graphene, such as quantum dots, fuel cells, filtration, coatings, polymer composites, and lubricants, are examined in-depth.
  • The Global Market for Graphene and 2D Materials 2024-2034 contains:
    Assessment of graphene by market including applications, key benefits, market megatrends, market drivers for graphene, technology drawbacks, competing materials, potential consumption of graphene to 2034 and main players.
  • Assessment of graphene materials (CVD graphene, graphene nanoplatelets, graphene oxide, etc), intermediate products (graphene masterbatches, dispersions, etc) and final products with graphene embedded (e.g.